Stocklytics Platform
Asset logo for symbol PHAT
Phathom Pharmaceuticals
PHAT43
$11.65arrow_drop_up2.91%$0.33
Asset logo for symbol PHAT
PHAT43

$11.65

arrow_drop_up2.91%
Key Stats
Open$11.50
Prev. Close$11.32
EPS-4.46
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$662.61M
PE Ratio-
LOWHIGH
Day Range11.37
11.82
52 Week Range6.06
17.01
Ratios
P/B Ratio25.37
Revenue-
Operating M. %-3,658.68%
Earnings$0.00
Earnings Growth %-1.96%
EBITDA Margin %-
ROE %-3,489.00%
EPS-4.46
Fundamentals
RPS$0.05
Gross Profit$515.00K
EBITDA-$206.54M
Total Debt$478.75M
P/S Ratio869.4x
Enterprise to EBITDA-2.20
Profit Margin75.51%
ROA-51.75%
Debt/Equity Ratio-
Payout Ratio-
Industry average yield3.06%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

PHATarrow_drop_down0.67%
US Healthcare Sectorarrow_drop_up1.02%
US Marketarrow_drop_up0.59%
warning
PHAT / Market
PHAT lose to the US Market which returned 0.59% over the last twenty four hours.
warning
PHAT / Healthcare Sector
PHAT lose to the US Healthcare sector which returned 1.02% over the last twenty four hours.

Phathom Pharmaceuticals (PHAT) Statistics

Phathom Pharmaceuticals Inc (PHAT) is a biopharmaceutical company that focuses on the development and commercialization of treatments for gastrointestinal diseases. The company is committed to addressing unmet medical needs and improving the lives of patients suffering from these conditions. In order to evaluate the performance and value of PHAT stock, it is important to consider various key statistics and metrics.

When looking at the valuation metrics of Phathom Pharmaceuticals Inc (PHAT), investors can analyze factors such as the stock's price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio. These metrics provide insights into how the stock is priced relative to the company's earnings, revenue, and book value. By comparing these metrics to industry benchmarks and historical performance, investors can gain a better understanding of the stock's valuation and potential for growth.

add Phathom Pharmaceuticals  to watchlist

Keep an eye on Phathom Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Phathom Pharmaceuticals (PHAT) stock's performance compared to its sector and the market over the past year?

Over the past year, Phathom Pharmaceuticals (PHAT) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 24.25%, Phathom Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 55.20%, it has fallen short of the market average. This comparison highlights Phathom Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.

help
What is the PE ratio of Phathom Pharmaceuticals (PHAT) stock?

The PE ratio for Phathom Pharmaceuticals (PHAT) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

help
What is the EPS of Phathom Pharmaceuticals (PHAT) stock?

The Earnings Per Share (EPS) for Phathom Pharmaceuticals (PHAT), calculated on a diluted basis, is -$4.46. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

help
What is the operating margin of Phathom Pharmaceuticals (PHAT) stock?

The operating margin for Phathom Pharmaceuticals (PHAT) is -3.66K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

help
What is the EBITDA of Phathom Pharmaceuticals (PHAT) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Phathom Pharmaceuticals (PHAT) is -$206.55M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

help
How much debt does Phathom Pharmaceuticals (PHAT) have?

Phathom Pharmaceuticals (PHAT) has a total debt of $478.75M. The net debt, which accounts for cash and cash equivalents against the total debt, is $146.82M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level